RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The findings confirm the antibody's potential to limit off-target exposure and mitigate toxicities associated with traditional monoclonal antibody therapies. This biodistribution study completes the preclinical package necessary for the upcoming IND application.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
- Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
- Acceleration of RAD204 Phase 1 dose escalation trial
- Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference
- Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
Later from Radiopharm Theranostics
- Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
- RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
- Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
- RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
- Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics